We are live on ! Find out more
ADCT icon

ADC Therapeutics

52 hedge funds and large institutions have $921M invested in ADC Therapeutics in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

214% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 7

27% more funds holding

Funds holding: 4152 (+11)

6.31% more ownership

Funds ownership: 30.48%36.79% (+6.3%)

8% less capital invested

Capital invested by funds: $1B → $921M (-$79.6M)

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

99% less call options, than puts

Call options by funds: $3K | Put options by funds: $336K

Holders
52
Holders Change
+11
Holders Change %
+26.83%
% of All Funds
1.05%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
16
Increased
22
Reduced
7
Closed
5
Calls
$3K
Puts
$336K
Net Calls
-$333K
Net Calls Change
-$333K

ADCT Hedge Fund Activity: Q3 2020 in Review

52 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q3 2020, worth a combined $921M — down 8% from $1B a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ADCT positions and 5 closed out — a net gain of 11 holders — while 22 added to existing stakes and 7 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $105M. The largest seller was Deerfield Management, cutting an estimated $8.66M.

  • 52 institutional investors held ADC Therapeutics (ADCT) as of Q3 2020, up from 41 in Q2 2020.
  • Funds reported $921M of ADC Therapeutics stock for Q3 2020, down 8% quarter-over-quarter.
  • 16 funds opened new ADC Therapeutics positions in Q3 2020 and 5 closed out, a net change of +11 holders.
  • The largest ADC Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $105M added.
  • The largest ADC Therapeutics seller in Q3 2020 was Deerfield Management, an estimated $8.66M sold.

Based on aggregated 13F filings for Q3 2020.